Potential impact of subsequent entry biologics in nephrology practice in Canada

Canadian Journal of Kidney Health and Disease

Volumn 1, Issue 1, 2014, Pages

  Martinusen, Daniel J ^a,d   Lo, Clifford ^a   Marin, Judith G ^b   Tsao, Nicole W ^c   Leung, Marianna ^b  

^a British Columbia Provincial Renal Agency   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d ROYAL JUBILEE HOSPITAL   (Canada)

Author keywords

Biologics; Biosimilars; Biotherapeutic products; Nephrology; Regulation; Subsequent entry biologics

Indexed keywords

ERYTHROPOIETIN;

CANADA; CHRONIC KIDNEY DISEASE; CLINICAL DECISION MAKING; DRUG INDUSTRY; EUROPEAN MEDICINES AGENCY; EXERCISE; HEALTH CARE COST; HEALTH CARE PRACTICE; HEALTH CARE SYSTEM; HUMAN; IMMUNOGENICITY; NEPHROLOGIST; OUTCOME ASSESSMENT; PHARMACOECONOMICS; PRIORITY JOURNAL; REVIEW;

EID: 84991037399     PISSN: None     EISSN: 20543581     Source Type: Journal    
DOI: 10.1186/s40697-014-0032-7     Document Type: Review

References (52)

1. Sweetman S: Martindale: The Complete Drug Reference. 37th edition. London: Pharmaceutical Press; 2011
2. Janssen Inc.: EPREX Product Monograph [Internet]. Toronto Ontario: Janssen; 2011.
3. Colcher D, Pavlinkova G, Beresford G, Booth BJ, Choudhury A, Batra SK: Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q J Nucl Med Off Publ Ital Assoc Nucl Med AIMN Int Assoc Radiopharmacol IAR 1998, 42(4):225-241.
4. What you need to know About Biosimilar Medicinal Products-A Consensus Information Document [Internet]. European Commission Enterprise and Industry; 2013 [cited 2014 Jan 26]. Available from: http://ec.europa.eu/ enterprise/sectors/healthcare/files/docs/biosimilars_report_en.pdf
5. Joung J, Robertson JS, Griffiths E, Knezevic I: WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products held at WHO Headquarters, Geneva, 19-20 April 2007. Biologicals 2008, 36(4):269-276.
6. Mikhail A, Farouk M: Epoetin biosimilars in Europe: five years on. Adv Ther 2013, 30(1):28-40.
7. Macdougall IC: Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another. Curr Med Res Opin 2004, 20(1):83-86.
8. Jelkmann W: Biosimilar epoetins and other "follow-on" biologics: update on the European experiences. Am J Hematol 2010, 85(10):771-780.
9. Combe C, Tredree RL, Schellekens H: Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacother J Hum Pharmacol Drug Ther 2005, 25(7):954-962.
10. ICH Q5E: Comparability of Biotechnological/Biological Prodcuts Subject to Changes in Their Manufacturing Process [Internet]. International Conference on Harmonization; 2003 Nov. Available from: http://www.ich.org/fileadmin/ Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_ Guideline.pdf
11. ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients [Internet]. International Conference on Harmonization; 2000 Nov. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/ Guidelines/Quality/Q7/Step4/Q7_Guideline.pdf
12. Government of Canada HC. Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs) [Health Canada, 2010] [Internet]. 2010 [cited 2014 Jan 5]. Available from: http://www.hc-sc.gc.ca/ dhp-mps/brgtherap/applic-demande/guides/seb-pbu/seb-pbu_2010-eng.php
13. Wang J, Chow S-C: On the regulatory approval pathway of biosimilar products. Pharm Basel Switz 2012, 5(4):353-368.
14. Government of Canada HC. Questions and Answers-Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs) [Health Canada, 2010] [Internet]. 2010 [cited 2014 Jan 5]. Available from: http://www.hc-sc.gc.ca/dhp-mps/brgtherap/applic-demande/guides/ seb-pbu/01-2010-seb-pbu-qa-qr-eng.php
15. Government of Canada HC. Summary Basis of Decision (SBD): Inflectra-2014 - Health Canada [Internet]. 2014 [cited 2014 Apr 8]. Available from: http://www. hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2014_ inflectra_159493-eng.php 16.
16. Health Product Vigilance Framework. Ottawa, Ontario: Health Canada; 2012 [cited 2014 Dec 5]. Available from http://www.hc-sc.gc.ca/dhp-mps/ alt_formats/pdf/pubs/medeff/fs-if/2012-hpvf-cvps/dhpvf-ecvps-eng.pdf
17. Draft Guideline on Similar Biological Medicinal Products-WC500142978.pdf [Internet]. Committee for Medicinal Products for Human Use, European Medicines Agency; 2013 [cited 2014 Feb 2]. Available from: http://www. ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/ WC500142978.pdf
18. Minghetti P, Rocco P, Cilurzo F, Del Vecchio L, Locatelli F: The regulatory framework of biosimilars in the European Union. Drug Discov Today 2012, 17(1-2):63-70.
19. Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants [Internet]. US Department of Health and Human Services Food and Drug Administration; 2013 Mar. Available from: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM345649.pdf
20. Scientific Considerations in Demonstrating Biosimilarity To A Reference Product [Internet]. US Department of Health and Human Services Food and Drug Administration; 2012 Feb. Available from: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128. pdf
21. Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product [Internet]. US Department of Health and Human Services Food and Drug Administration; 2012 Feb. Available from: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM291134.pdf
22. Biosimilars: Questions and answers regarding implementation of the biologics price competition and innovation act of 2009 [Internet]. US Department of Health and Human Services Food and Drug Administration; 2012 Feb. Available from: http://www.fda.gov/downloads/Drugs/Guidances/ UCM273001.pdf
23. Evaluation of biosimilars [Internet]. Australian Government Department of Health-Therapeutic Goods Administration; 2013 Jul [cited 2013 Dec 29]. Report No.: 1. Available from: http://www.tga.gov.au/industry/pm-argpmbiosimilars- 00.htm#.UsCte_ZZV2d
24. Power D: Licensing and prescribing biosimilars in Australia. Generics Biosimilars Initiat J 2013, 2(3):152-154.
25. Derbyshire M. Biosimilar development and regulation in Japan-GaBI Journal. Generics Biosimilars Initiat J [Internet]. 2013 [cited 2014 Jan 14];2(4). Available from: http://gabi-journal.net/biosimilar-development-and-regulation- in-japan.html
26. Konangi S, Raviteja M, Gupta V: Comparison of global regulatory approvals for biosimilar products. Int J PharmTech Res 2013, 5(3):924-935.
27. Statistics c = AU; o = Commonwealth of A ou = Australian B of. Population clock [Internet]. [cited 2014 Jan 14]. Available from: http://www.abs.gov.au/ ausstats/abs@.nsf/0/1647509ef7e25faaca2568a900154b63?opendocument
28. WHO informal consultation on international nonproprietary names (INN) policy for biosimilar products [Internet]. Geneva: World Health Organization; 2006 Sep. Available from: http://www.who.int/medicines/services/inn/ BiosimilarsINN_Report.pdf?ua=1
29. Rickwood S: Shaping the Biosimilars Opportunity: A global Perspective on the Evolving Biosimilars Landscape [Internet]. London: IMS Health; 2011. Available from: http://www.imshealth.com/ims/Global/Content/Home%20Page% 20Content/IMS%20News/Biosimilars_Whitepaper.pdf.
30. Biswas P: Pharmacovigilance in Asia. J Pharmacol Pharmacother 2013, 4(Suppl1):S7-S19.
31. Yamaguchi T, Arato T: Quality, safety and efficacy of follow-on biologics in Japan. Biol J Int Assoc Biol Stand 2011, 39(5):328-332.
32. Challand R. Global Biosimilar Development [Internet]. PRA; Available from: http://www.healthtrustpg.com/biosimilars/pdf/pra.pdf
33. Haas M: Bettering China's Biosimilars. Chicago): BioCentury; 2013:A9-A11.
34. Malhotra H: Biosimilars and non-innovator biotherapeutics in India: an overview of the current situation. Biol J Int Assoc Biol Stand 2011, 39(5):321-324.
35. Singh G, Kamboj V: Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India. India: Department of Biotechnology: Ministry of Science and Technology Government of India; 2012.
36. Gauging the Biosimilar Effect: Will the Market Boom or Bust? Firstword Dossier: Doctor's Guide Publishing Limited; New York 2012.
37. Chang P. Korea's Celltrion, Partner Hospira Win Drug Procurement Bid In Norway For Infliximab Biosimilar: PharmAsia News: Elsevier Business Intelligence [Internet]. PhamrAsia News. 2014 [cited 2014 Feb 1]. Available from: http://www. elsevierbi.com/publications/pharmasia-news/2014/1/29/koreas-celltrion-partnerhospira- win-drug-procurement-bid-in-norway-for-infliximab-biosimilar
38. Rovira, J, Espín J, Garcia L, Olry de Labry A. The Impact of Biosimilars' Entry in The Eu Market [Internet]. Andalusian School of Public Health; 2011 Jan [cited 2014 Jan 26]. Available from: http://ec.europa.eu/enterprise/sectors/ healthcare/files/docs/biosimilars_market_012011_en.pdf
39. Narang P: Biosimilar Market Growth Contingent on the US [Internet] Datamonitor. 2009.
40. BioPharma Today: European Biosimilars' Market Performance Mirrors US Legislative Progress: Slow but Steady [Internet]. [cited 2014 Jan 26]. Available from: http://www.biopharmatoday.com/2009/05/european-biosimilarsmarket- performance-mirrors-us-legislative-progress-slow-but-steady-.html
41. EGA_Docket No FDA-2010-N-0477-EGA_Docket_No_FDA-2010-N-0477.pdf [Internet]. FDA; 2010 [cited 2014 Feb 2]. Available from: http://198.170.119.137/ doc/EGA_Docket_No_FDA-2010-N-0477.pdf
42. Calo-Fernandez B, Martinez-Hurtado JL: Biosimilars: Company Strategies to Capture Value from the Biologics Market. Pharmaceuticals 2012, 5(12):1393-1408.
43. Rickwood S, Iervolino A: Shaping the Biosimilars Opportunity: A Global Perspective on the Evolving Biosimilars Landscape [Internet]. London: IMS Health; 2011.
44. Agencarelli. Anti-TNF Biosimilar Prices-How low will they go? | ALSCG Company Blog [Internet]. [cited 2014 Feb 1]. Available from: http://blog.alscg. com/?p=53
45. Scott B, Klein A, Wang J. Biosimilar monoclonal antibodies: A canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation [Internet]. J Clin Pharmacol. 2014 [cited 2014 Oct 1]. Available from: http://onlinelibrary.wiley.com/doi/ 10.1002/jcph.339/abstract
46. Bennett CL, Cournoyer D, Carson KR, Rossert J, Luminari S, Evens AM, Locatelli F, Belknap SM, McKoy JM, Lyons EA, Kim B, Sharma R, Costello S, Toffelmire EB, Wells GA, Messner HA, Yarnold PR, Trifilio SM, Raisch DW, Kuzel TM, Nissenson A, Lim LC, Tallman MS, Casadevall N: Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 2005, 106(10):3343-3347.
47. Rossert J, Casadevall N, Eckardt K-U: Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol JASN 2004, 15(2):398-406.
48. Covic A, Cannata-Andia J, Cancarini G, Coppo R, Frazão JM, Goldsmith D, Ronco P, Spasovski GB, Stenvinkel P, Utas C, Wiecek A, Zoccali C, London G: Biosimilars and biopharmaceuticals: what the nephrologists need to know-a position paper by the ERA-EDTA Council. Nephrol Dial Transplant Off Pub Eur Dial Transpl Assoc-Eur Ren Assoc 2008, 23(12):3731-3737.
49. Bouchet J-L, Brunet P, Canaud B, Chanliau J, Combe C, Deray G, Pascal H, Olivier K, Elena L, Patrick N, Jean-Paul O, Mira P, Jean-Philippe R, Eric S, David V: Recommandations d'utilisation des biosimilaires de l'érythropoïétine (EPO). Propositions de la Société de néphrologie, de la Société francophone de dialyse et de la Société de néphrologie pédiatrique. Néphrologie Thérapeutique 2009, 5(1):61-66.
50. Vital EM, Kay J, Emery P: Rituximab biosimilars. Expert Opin Biol Ther 2013, 13(7):1049-1062.
51. NewsletterINNs_Nov06_WhatsNew_000.pdf [Internet]. [cited 2014 Feb 17]. Available from: http://www.isdbweb.org/documents/uploads/newsletter_ open/NewsletterINNs_Nov06_WhatsNew_000.pdf
52. Allin P. French Biosimilar Law-No generics substitution policy [Internet]. European Biopharmaceutical Enterprises; 2014 Jan [cited 2014 Jan 28]. Available from: http://www.ebe-biopharma.eu/uploads/Modules/Newsroom/ ebe-bs-statement-final_24.01.2014.pdf